EugeneShenderovMDD.Phil., F.A.C.P.(He/Him)

Oncology • Baltimore, MD

Genitourinary Oncology

Assistant Professor of Oncology and Cancer Research Immunology

Join to view full profile

Dr. Shenderov is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shenderov's full profile

Already have an account?

Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2016 - 2018
Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2013 - 2016
Johns Hopkins University School of MedicineClass of 2013, MD
University of OxfordD.Phil, Tumour Immunology, 2005 - 2009

Certifications & Licensure

DC State Medical License 2023 - 2027
PA State Medical License 2024 - 2026
VA State Medical License 2023 - 2026
MD State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer Start of enrollment: 2024 Feb 16
Recruiting
Phase 2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.
Ezra G Baraban, Evangelia Vlachou, Sunil Patel, Max Kates, Burles Johnson
The Prostate. 2025-01-02
Routine cold storage leads to hyperacute graft loss in pig-to-primate kidney xenotransplantation; hypothermic machine perfusion may be preferred preservation modality ...
Kazuhiko Yamada, Yu Hisadome, Daniel Eisenson, WeiLi Chen, Alex Schulick
Research Square. 2024-12-18
2 citations
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Carly D Miller, John R Lozada, Nicholas A Zorko, Andrew Elliott, Allison Makovec
Cancer Research Communications. 2024-05-30

Lectures

Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Immunotherapy Could Be Effective for Treating Prostate Cancer: StudyApril 9th, 2023
Health News | Immunotherapy Could Be Effective for Treatment of Prostate Cancer: StudyApril 9th, 2023
Study Shows How Novel Immunotherapy Helps Fight High-Risk Prostate Cancer, ET HealthWorldApril 8th, 2023
Join now to see all